BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Manns MP, Pockros PJ, Norkrans G, Smith CI, Morgan TR, Häussinger D, Shiffman ML, Hadziyannis SJ, Schmidt WN, Jacobson IM. Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin. J Viral Hepat. 2013;20:524-529. [PMID: 23808990 DOI: 10.1111/jvh.12074] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Muriel P, Ramos-tovar E, Montes-páez G, Buendía-montaño L. Experimental Models of Liver Damage Mediated by Oxidative Stress. Liver Pathophysiology. Elsevier; 2017. pp. 529-46. [DOI: 10.1016/b978-0-12-804274-8.00040-0] [Cited by in Crossref: 12] [Article Influence: 2.4] [Reference Citation Analysis]
2 Tillmann HL. Hepatitis C virus infection: when is a cure not a cure? J Infect Dis 2014;209:6-8. [PMID: 24127562 DOI: 10.1093/infdis/jit543] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
3 Ippolito G, Antonelli G, Capobianchi M, Lanini S. Hepatitis C virus treatment revolution: need for close monitoring. Clinical Microbiology and Infection 2014;20:O790-1. [DOI: 10.1111/1469-0691.12693] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
4 Shiffman ML, Gunn NT. Management and Treatment of Chronic HBV and HCV Co-Infection and the Impact of Anti-Viral Therapy. Curr Hepatology Rep 2017;16:169-77. [DOI: 10.1007/s11901-017-0352-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
5 Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006. [PMID: 28252637 DOI: 10.1038/nrdp.2017.6] [Cited by in Crossref: 189] [Cited by in F6Publishing: 162] [Article Influence: 37.8] [Reference Citation Analysis]
6 Fabrizi F, Messa P. Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population? Expert Rev Clin Pharmacol. 2015;8:785-793. [PMID: 26365524 DOI: 10.1586/17512433.2015.1086266] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
7 Shiffman ML, James AM, Long AG, Alexander PC. Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin. Am J Gastroenterol. 2015;110:1179-1185. [PMID: 26215530 DOI: 10.1038/ajg.2015.218] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
8 Abdellatif AAH, Alsowinea AF. Approved and marketed nanoparticles for disease targeting and applications in COVID-19. Nanotechnology Reviews 2021;10:1941-77. [DOI: 10.1515/ntrev-2021-0115] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. Clin Infect Dis. 2016;62:683-694. [PMID: 26787172 DOI: 10.1093/cid/civ948] [Cited by in Crossref: 178] [Cited by in F6Publishing: 163] [Article Influence: 29.7] [Reference Citation Analysis]
10 Khullar V, Firpi RJ. Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol 2015; 7(14): 1843-1855 [PMID: 26207166 DOI: 10.4254/wjh.v7.i14.1843] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
11 Howe AY, Long J, Nickle D, Barnard R, Thompson S, Howe J, Alves K, Wahl J. Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C. Antiviral Res 2015;113:71-8. [PMID: 25446895 DOI: 10.1016/j.antiviral.2014.10.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
12 Mak LY, Seto WK, Lai CL, Yuen MF. An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. Expert Opin Drug Metab Toxicol 2018;14:483-91. [PMID: 29718748 DOI: 10.1080/17425255.2018.1472236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
13 Krassenburg LAP, Zanjir WR, Georgie F, Stotland E, Janssen HLA, Hansen BE, Feld JJ. Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection. Clin Infect Dis 2021;72:780-6. [PMID: 32052014 DOI: 10.1093/cid/ciaa144] [Reference Citation Analysis]
14 Abd Alla MDA, El Awady MK, Dawood RM, Elhawary MA, Al-Azhari SS, Galal AGM. Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis. Arch Virol 2018;163:2765-74. [PMID: 29971486 DOI: 10.1007/s00705-018-3922-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
15 Sussman NL, Remien CH, Kanwal F. The end of hepatitis C. Clin Gastroenterol Hepatol 2014;12:533-6. [PMID: 24480676 DOI: 10.1016/j.cgh.2014.01.025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
16 Terrault NA, Hassanein TI. Management of the patient with SVR. Journal of Hepatology 2016;65:S120-9. [DOI: 10.1016/j.jhep.2016.08.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
17 Farjadian F, Ghasemi A, Gohari O, Roointan A, Karimi M, Hamblin MR. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. Nanomedicine (Lond) 2019;14:93-126. [PMID: 30451076 DOI: 10.2217/nnm-2018-0120] [Cited by in Crossref: 143] [Cited by in F6Publishing: 100] [Article Influence: 35.8] [Reference Citation Analysis]
18 Zayed RA, Omran D, Zayed AA, Elmessery LO. Determinants of Infection Outcome in HCV-Genotype 4. Viral Immunol. 2017;30:560-567. [PMID: 28731371 DOI: 10.1089/vim.2017.0071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
19 Manne V, Akhtar E, Saab S. Cirrhosis regression in patients with viral hepatitis B and C: a systematic review. J Clin Gastroenterol. 2014;48:e76-e84. [PMID: 24921210 DOI: 10.1097/mcg.0000000000000162] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.9] [Reference Citation Analysis]
20 Aqel BA, Vargas HE. Hepatitis C virus infection in nonliver solid organ transplant candidates and recipients. Curr Opin Organ Transplant 2015;20:259-66. [PMID: 25944237 DOI: 10.1097/MOT.0000000000000195] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
21 Manns MP, von Hahn T. Novel therapies for hepatitis C — one pill fits all? Nat Rev Drug Discov 2013;12:595-610. [DOI: 10.1038/nrd4050] [Cited by in Crossref: 140] [Cited by in F6Publishing: 132] [Article Influence: 15.6] [Reference Citation Analysis]
22 Surjadi M. Chronic Hepatitis C Screening, Evaluation, and Treatment Update in the Age of Direct-Acting Antivirals. Workplace Health Saf 2018;66:302-9. [PMID: 29359645 DOI: 10.1177/2165079917751479] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Fayek SA, Quintini C, Chavin KD, Marsh CL. The Current State of Liver Transplantation in the United States: Perspective From American Society of Transplant Surgeons (ASTS) Scientific Studies Committee and Endorsed by ASTS Council. Am J Transplant 2016;16:3093-104. [PMID: 27545282 DOI: 10.1111/ajt.14017] [Cited by in Crossref: 57] [Cited by in F6Publishing: 44] [Article Influence: 9.5] [Reference Citation Analysis]
24 Verstegen MM, Pan Q, van der Laan LJ. Gene therapies for hepatitis C virus. Adv Exp Med Biol 2015;848:1-29. [PMID: 25757613 DOI: 10.1007/978-1-4939-2432-5_1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
25 Wiznia LE, Laird ME, Franks AG Jr. Hepatitis C virus and its cutaneous manifestations: treatment in the direct-acting antiviral era. J Eur Acad Dermatol Venereol. 2017;31:1260-1270. [PMID: 28252812 DOI: 10.1111/jdv.14186] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
26 Pasqualotto AC, Almeida CS, Kliemann DA, Barcellos GB, Queiroz-Telles F, Abdala E, Resende M, Batista FP, Vidal JE, Rocha J, Raboni SM, Cimerman S, Gales AC. Top 10 evidence-based recommendations from the Brazilian Society of Infectious Diseases for the Choosing Wisely Project. Braz J Infect Dis 2019;23:331-5. [PMID: 31562852 DOI: 10.1016/j.bjid.2019.08.004] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Loo N, Hanysak B, Mann J, Ramirez R, Kim J, Mitchell R, Van Frank T, Guerrero R, Hinojosa K, Christensen K, Pedicone LD, Alkhouri N, Wells J, Landaverde C, Rodas F, Lawitz E, Poordad F. Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance. Medicine (Baltimore) 2019;98:e16254. [PMID: 31261592 DOI: 10.1097/MD.0000000000016254] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
28 Lee YA, Friedman SL. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res 2014;107:23-30. [PMID: 24726738 DOI: 10.1016/j.antiviral.2014.03.012] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 10.3] [Reference Citation Analysis]
29 Cheinquer H. Treatment of chronic hepatitis C virus infection in the near future. Annals of Hepatology 2013;12:854-9. [DOI: 10.1016/s1665-2681(19)31288-8] [Reference Citation Analysis]
30 Masip M, Tuneu L, Pagès N, Torras X, Gallego A, Guardiola JM, Faus MJ, Mangues MA. Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment. Int J Clin Pharm 2015;37:1143-51. [PMID: 26267215 DOI: 10.1007/s11096-015-0177-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
31 de Bruijn W, Ibáñez C, Frisk P, Bak Pedersen H, Alkan A, Vella Bonanno P, Brkičić LS, Bucsics A, Dedet G, Eriksen J, Fadare JO, Fürst J, Gallego G, Godói IP, Guerra Júnior AA, Gürsöz H, Jan S, Jones J, Joppi R, Kerman S, Laius O, Madzikwa N, Magnússon E, Maticic M, Markovic-Pekovic V, Massele A, Ogunleye O, O'Leary A, Piessnegger J, Sermet C, Simoens S, Tiroyakgosi C, Truter I, Thyberg M, Tomekova K, Wladysiuk M, Vandoros S, Vural EH, Zara C, Godman B. Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. Front Pharmacol 2016;7:197. [PMID: 27516740 DOI: 10.3389/fphar.2016.00197] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
32 Airewele NE, Shiffman ML. Chronic Hepatitis B Virus in Patients with Chronic Hepatitis C Virus. Clin Liver Dis 2021;25:817-29. [PMID: 34593155 DOI: 10.1016/j.cld.2021.06.008] [Reference Citation Analysis]
33 Barreiro P, Fernandez-Montero JV, de Mendoza C, Labarga P, Soriano V. Towards hepatitis C eradication from the HIV-infected population. Antiviral Res 2014;105:1-7. [PMID: 24534673 DOI: 10.1016/j.antiviral.2014.02.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
34 Garai P, Gogoi M, Gopal G, Radhakrishnan Y, Nandakumar KS, Chakravortty D. The basics and advances of immunomodulators and antigen presentation: a key to development of potent memory response against pathogens. Expert Opin Biol Ther 2014;14:1383-97. [PMID: 24897303 DOI: 10.1517/14712598.2014.925871] [Reference Citation Analysis]
35 Höner zu Siederdissen C, Manns MP, Cornberg M. [Which treatment options are validated for chronic viral hepatitis?]. Internist (Berl) 2013;54:1427-8, 1430-3. [PMID: 24258199 DOI: 10.1007/s00108-013-3319-3] [Reference Citation Analysis]
36 Mancuso ME, Linari S, Santagostino E, Bartolozzi D, D'Ambrosio R, Borghi M, Lampertico P, Peyvandi F, Castaman G, Aghemo A. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study. Liver Int 2020;40:1062-8. [PMID: 31876354 DOI: 10.1111/liv.14337] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
37 Flisiak R, Janczewska E, Łucejko M, Karpińska E, Zarębska-Michaluk D, Nazzal K, Bolewska B, Białkowska J, Berak H, Fleischer-Stępniewska K, Tomasiewicz K, Karwowska K, Simon K, Piekarska A, Tronina O, Tuchendler E, Garlicki A. Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study. J Viral Hepat 2018;25:1298-305. [PMID: 29888828 DOI: 10.1111/jvh.12945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
38 French SW. How to prevent alcoholic liver disease. Exp Mol Pathol. 2015;98:304-307. [PMID: 25758202 DOI: 10.1016/j.yexmp.2015.03.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
39 Attar BM, Van Thiel D. A New Twist to a Chronic HCV Infection: Occult Hepatitis C. Gastroenterol Res Pract. 2015;2015:579147. [PMID: 26221136 DOI: 10.1155/2015/579147] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
40 Marron MM, Anderson SJ, Garrity J, Reynolds CF 3rd, Lotrich FE. Association of Baseline Sleep Quality With Trajectories of Depressive Symptoms in Patients Undergoing Interferon Treatment. Psychosom Med 2015;77:911-20. [PMID: 26407225 DOI: 10.1097/PSY.0000000000000231] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
41 Shiffman ML. The next wave of hepatitis C virus: The epidemic of intravenous drug use. Liver Int 2018;38:34-9. [DOI: 10.1111/liv.13647] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
42 Righi E, Londero A, Carnelutti A, Baccarani U, Bassetti M. Impact of new treatment options for hepatitis C virus infection in liver transplantation. World J Gastroenterol 2015; 21(38): 10760-10775 [PMID: 26478668 DOI: 10.3748/wjg.v21.i38.10760] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
43 Schwarz KB, Molleston JP, Jonas MM, Wen J, Murray KF, Rosenthal P, Gonzalez-peralta RP, Lobritto SJ, Mogul D, Pavlovic V, Warne C, Wat C, Thompson B. Durability of Response in Children Treated With Pegylated Interferon alfa-2a ± Ribavirin for Chronic Hepatitis C. Journal of Pediatric Gastroenterology & Nutrition 2016;62:93-6. [DOI: 10.1097/mpg.0000000000000929] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
44 Shiffman ML, Benhamou Y. Cure of HCV related liver disease. Liver Int 2015;35 Suppl 1:71-7. [PMID: 25529090 DOI: 10.1111/liv.12734] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
45 Pruß A, Chandrasekar A, Sánchez-Ibáñez J, Lucas-Samuel S, Kalus U, Rabenau HF. Algorithms for the Testing of Tissue Donors for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus. Transfus Med Hemother 2021;48:12-22. [PMID: 33708048 DOI: 10.1159/000513179] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Wiesmann F, Braun P. Significance of HCV RNA monitoring in the era of new potent therapies. Expert Rev Anti Infect Ther 2016;14:837-44. [PMID: 27424603 DOI: 10.1080/14787210.2016.1214355] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
47 Jacobson IM, Lim JK, Fried MW. American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. Gastroenterology. 2017;152:1578-1587. [PMID: 28344022 DOI: 10.1053/j.gastro.2017.03.018] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 9.8] [Reference Citation Analysis]
48 Manns MP, Vierling JM, Bacon BR, Bruno S, Shibolet O, Baruch Y, Marcellin P, Caro L, Howe AY, Fandozzi C, Gress J, Gilbert CL, Shaw PM, Cooreman MP, Robertson MN, Hwang P, Dutko FJ, Wahl J, Mobashery N. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology 2014;147:366-76.e6. [PMID: 24727022 DOI: 10.1053/j.gastro.2014.04.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
49 AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus: HEPATITIS C VIRUS GUIDANCE PANEL. Hepatology 2015;62:932-54. [DOI: 10.1002/hep.27950] [Cited by in Crossref: 844] [Cited by in F6Publishing: 832] [Article Influence: 120.6] [Reference Citation Analysis]
50 Lee KS, Quintiliani L, Heinz A, Johnson NL, Xuan Z, Truong V, Lasser KE. A financial incentive program to improve appointment attendance at a safety-net hospital-based primary care hepatitis C treatment program. PLoS One 2020;15:e0228767. [PMID: 32045447 DOI: 10.1371/journal.pone.0228767] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
51 Wedemeyer H, Reimer J, Sandow P, Hueppe D, Lutz T, Gruengreiff K, Goelz J, Christensen S, Pfeiffer-Vornkahl H, Alshuth U, Manns MP. Long-term outcome of chronic hepatitis C virus infection in a real-world setting: The German LOTOS study. Liver Int 2017;37:1468-75. [PMID: 28247572 DOI: 10.1111/liv.13399] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
52 Gambato M, Lens S, Navasa M, Forns X. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. J Hepatol. 2014;61:S120-S131. [PMID: 25443340 DOI: 10.1016/j.jhep.2014.07.020] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
53 Chen AY, Zeremski M, Chauhan R, Jacobson IM, Talal AH, Michalak TI. Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy. PLoS One 2013;8:e80078. [PMID: 24278242 DOI: 10.1371/journal.pone.0080078] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
54 Méndez-Lagares G, Lu D, Chen C, Terrault N, Segal MR, Khalili M, Monto A, Shen H, Manos MM, Lanier LL, Ryan JC, McCune JM, Hartigan-O'Connor DJ. Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success. J Immunol 2018;200:1124-32. [PMID: 29263212 DOI: 10.4049/jimmunol.1701364] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
55 Haber B, Alonso E, Pedreira A, Rodriguez-Baez N, Ciocca M, Lacaille F, Lang T, Gonzalez T, Goodman Z, Yang Z. Long-Term Follow-Up of Children Treated With Peginterferon and Ribavirin for Hepatitis C Virus Infection. J Pediatr Gastroenterol Nutr. 2017;64:89-94. [PMID: 27111344 DOI: 10.1097/mpg.0000000000001239] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
56 Shiffman ML, Long AG, James A, Alexander P. My treatment approach to chronic hepatitis C virus. Mayo Clin Proc 2014;89:934-42. [PMID: 24867397 DOI: 10.1016/j.mayocp.2014.04.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
57 Weber J, Sahoo MK, Taylor N, Shi RZ, Pinsky BA. Evaluation of the Aptima HCV Quant Dx Assay Using Serum and Dried Blood Spots. J Clin Microbiol 2019;57:e00030-19. [PMID: 30760534 DOI: 10.1128/JCM.00030-19] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]